Compare Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Sht-Term Inflation-Protected Sec Idx ETF vs Zoetis Inc — how do they compare? Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.65, while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VTIP | ZTS | |
|---|---|---|
52-Week High | $50.75 | $156.76 |
52-Week Low | $49.39 | $71.91 |
Market Cap | — | $31.95B |
Sector | — | Health |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTIP trades at $49.63, down 0.14% with a bearish technical signal. The Vanguard Short-Term Inflation-Protected Securities ETF provides inflation protection through short-term TIPS, offering an expected 3.8% return amid current inflation levels. Recent institutional activity shows mixed positioning with some firms increasing holdings while others trim positions.
The ETF presents a defensive play against persistent inflation above the Fed's 2% target, though rising interest rates pose valuation risks. Short duration reduces interest rate sensitivity compared to longer-term bonds, making it suitable for inflation-hedging portfolios in the current economic environment.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
